Status:
UNKNOWN
Utility Assessment of a Pharmacy-to-Dose Daptomycin
Lead Sponsor:
Methodist Health System
Conditions:
Antibiotics Causing Adverse Effects in Therapeutic Use
Brief Summary
A pharmacy-to-dose (PTD) service, also referred to as pharmacy-based dosing, describes an established practice where providers can consult pharmacists for the dosing of various medications. Consulted ...
Detailed Description
A pharmacy-to-dose (PTD) service, also referred to as pharmacy-based dosing, describes an established practice where providers can consult pharmacists for the dosing of various medications. Consulted ...
Eligibility Criteria
Inclusion
- ≥ 18 years old
- Have weight and renal function documented prior to daptomycin order entry
- Received at least one dose of daptomycin at any MHS facility
Exclusion
- Patients will be excluded if daptomycin was started at an outside facility and their dose was continued during their inpatient stay.
Key Trial Info
Start Date :
December 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 15 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05224687
Start Date
December 15 2021
End Date
December 15 2022
Last Update
February 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Methodist Dallas Medical Center
Dallas, Texas, United States, 75203